Pharmaceutical CDMO Market by Product Type (API and FDF), Dosage Form (Solid, Semi-solid, Liquid, and Others), Operations (Clinical and Commercial), Therapeutic Modality (Small Molecules and Biologics), End-users (Small Pharmaceuticalceuticals, Mid-sized Pharmaceuticalceuticals and Large Pharmaceuticalceuticals), Key Regions (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America), Key Companies – Global Forecast to 2030
In recent years, pharmaceutical outsourcing has noticeably grown amongst pharmaceutical companies and drug developers. The continuous increase in outsourcing different or all stages of drug substance development and manufacturing to CDMOs can be ascribed to the specialized services such as, formulation development, extraction, fermentation, sourcing, packaging and other offered by CDMOs that pharmaceutical companies may not possess in-house. According to Pfizer Centre One, there are close to 300 active CDMOs offering services to the pharmaceutical industry. It is worth mentioning that with the rising need for innovative / generic drugs, increasing research and development investments by CDMOs, need for decreasing drug’s time to market and emphasis on regulatory compliance the pharma CDMO sector is expected to play a vital role in offering outsourcing services, therefore, the demand for pharma CDMOs will grow in the coming decade.
Wissen Research analyses that the global pharmaceutical CDMO market is estimated at ~USD 155 billion in 2023 and is projected to reach ~USD 260 billion by 2030, expected to grow at a CAGR of ~7.2% during the forecast period, 2023-2030.
Driving Factor: Rising adoption of advanced technologies
Given the increasing number of complex compositions of drug / therapies, the CDMOs are forced to adopt latest technologies. By utilizing advanced methods / technologies, CDMOs offer high quality compounds as such advancements improve efficiency of operations, therefore, positions pharma CDMOs as one-stop solution for pharmaceutical stakeholders.
Opportunity: Increasing number of small and mid-sized drug developers and pharmaceutical CDMOs service providers in emerging markets
Due to their cost advantages and favourable regulations, emerging regions have become the outsourcing hubs. Factors such as, low labor and manufacturing cost are anticipated to offer discernible opportunities for the growth of pharma CDMOs market in the near future.
Challenge: Growing costs and balancing capacity utilization impacts growth and operations of CDMOs
Rising cost, especially with fluctuations in raw material costs and labor costs has become a constant challenge and thus pressurize CDMOs in managing operational costs while maintaining quality and compliance. Further, with variable project timelines and client demands, the capacity underutilization / overutilization leads to inefficiencies and financial strain with the risk of compromising quality and timelines.
The pharmaceutical CDMO market report offers information on the latest advancements in the industry, as well as service portfolio analysis, supply chain/value chain analysis, market share, and the effects of localized and domestic players. It also analyzes potential revenue opportunities and changes in market regulations, as well as market size, category market growth, application dominance, product approvals, service launches, geographic expansions, and technological innovations. For an Analyst Brief and other information on the pharmaceutical CDMO market, get in touch with Wissen Research. Our staff can assist you in making well-informed decisions that will lead to market expansion.
Active Pharmaceutical Ingredients (API) are holds largest rate within the pharma CDMO market by product type
The pharma CDMO market is segmented into API and FDF based on type of product. In 2024, API manufacturing segment is holding majority share and this trend likely to remain the same throughout the forecast period. This trend can be ascribed to the increasing demand for targeted cancer and other health problems.
Solid dose formulations captured majority share of pharma CDMO market by dosage form
Solid, semi-solid, liquid and other dose formulations are the key segments that the pharma CDMO service providers are available in. Currently, the sold dose formulation segment captures the largest share out of all these dosage forms. This can be attributed to the fact that capsules, tablets and powders have longer shelf life, are easy to ingest with fixed amount of active ingredients.
North America to dominate the current pharma CDMO market and Asia-Pacific to witness the highest growth
Currently, the US hold the majority share and is the primary hub for outsourcing to pharmaceutical companies and developers. However, Asian countries, especially India and China are anticipated to remain the leading CDMO growth markets during the forecast decade. Key elements supporting this trend includes high demand for advanced and reliable medicines, growing healthcare infrastructure, lower cost of manufacturing and comparatively less stringent regulatory framework, all of which are anticipated to fuel growth in emerging Asia-Pacific region.
Major Companies and Market Share Insights in Pharmaceutical CDMO Market Report
Major players operating in pharmaceutical CDMO market are Thermo Fisher Scientific, Inc., Lonza, Samsung Biologics, Pfizer Centre One, Recipharm AB, Bushu Pharmaceuticals Ltd., Catalent, Inc., LabCorp, WuXi AppTec, Inc., Piramal Pharmaceutical Solutions among others.
EuroAPI signed a strategic agreement with Priothera with an aim to develop and manufacture latter company’s oncology molecule, mocravimod. (June 2024)
UCB of Belgium expanded its collaboration with Samsung Biologics for the manufacturing of former company’s new drug substance (an anti-Tau candidate) for the treatment of progressive supranuclear palsy (PSP). (March 2024)
Recipharm AB entered a strategic collaboration with Oz-UK for the development and manufacturing of green pressurized metered dose inhalers (pMDIs). (December 2023)
Introduction
Market Definition
Pharmaceutical Contract Development and Manufacturing Organizations (CDMO) are third-party service providers, that handles all stages of innovation, development and manufacturing of drug substances. Services such as, formulation, analytical services, sterilization, blending, coating, packaging, converting and others are provided by the CDMOs.
Sources: Company Websites and Wissen Research Analysis.
Sources: Wissen Research Analysis.
Key Stakeholders
Key objectives of the Study
Research Methodology
The aim of the study is to examine the key market forces such as drivers, opportunities, restraints, challenges, and strategies of key leaders. To monitor company advancements such as patents granted, product launches, expansions, and collaborations of key players, analyzing their competitive landscape based on various parameters of business and product strategy. Markey sizing will be estimated using top-down and bottom-up approaches. Using market breakdown and data triangulation techniques, market sizing of segments and sub-segments will be estimated.
FIGURE: RESEARCH DESIGN
Sources: Wissen Research Analysis.
Research Approach
Collecting Secondary Data
The process of collating secondary research data involves the utilization of databases, secondary sources, annual reports, investor presentations, directories, and SEC filings of companies. Secondary research will be utilized to identify and gather information beneficial for the in-depth, technical, market-oriented, and commercial analysis of the pharmaceutical CDMO market. A database of the key industry leaders will also be compiled using secondary research.
Collecting Primary Data
The primary research data will be conducted after acquiring knowledge about the pharmaceutical CDMO market scenario through secondary research. A significant number of primary interviews will be conducted with stakeholders from both the demand and supply side (including various industry experts, such as Vice Presidents (VPs), Chief X Officers (CXOs), Directors from business development, marketing and product development teams, product manufacturers) across major countries of Europe, Asia-Pacific, North America, Latin America, and Middle East. Primary data for this report will be collected through questionnaires, emails, and telephonic interviews.
FIGURE: BREAKDOWN OF PRIMARY INTERVIEWS FROM SUPPLY SIDE
FIGURE: BREAKDOWN OF PRIMARY INTERVIEWS FROM DEMAND SIDE
FIGURE: PROPOSED PRIMARY PARTICIPANTS FROM DEMAND AND SUPPLY SIDE
Note: Above mention companies are non-exhaustive.
Market Size Estimation
All major manufacturers offering various pharmaceutical CDMO services will be identified at the global / regional level. Revenue mapping will be done for the major players, which will further be extrapolated to arrive at the global market value of each type of segment. The market value of pharmaceutical CDMO market will also split into various segments and sub segments at the region level based on:
FIGURE: REVENUE MAPPING BY COMPANY (ILLUSTRATION)
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
FIGURE: REVENUE SHARE ANALYSIS OF KEY PLAYERS (SUPPLY SIDE)
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
FIGURE: MARKET SIZE ESTIMATION TOP-DOWN AND BOTTOM-UP APPROACH
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
FIGURE: ANALYSIS OF DROCS FOR GROWTH FORECAST
Sources: Pharma and Biopharma Outsourcing Association (PBOA), CDMO France Association, Contract Pharma, The European Federation of Pharmaceutical Industries and Associations (EFPIA), The Japan CMO Association (JCMOA), National Health Institution (NIH), Company Website, Press Releases, Annual Reports, Paid Data Sources, and Wissen Research Analysis.
FIGURE: GROWTH FORECAST ANALYSIS UTILIZING MULTIPLE PARAMETERS
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
Research Design
After arriving at the overall market size-using the market size estimation processes-the market will be split into several segments and sub segment. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub segment, the data triangulation, and market breakdown procedures will be employed, wherever applicable. The data will be triangulated by studying various factors and trends from both the demand and supply sides in the pharmaceutical CDMO market.
Sources: Pharma and Biopharma Outsourcing Association (PBOA), CDMO France Association, Contract Pharma, The European Federation of Pharmaceutical Industries and Associations (EFPIA), The Japan CMO Association (JCMOA), National Health Institution (NIH), Company Website, Press Releases, Annual Reports, Paid Data Sources, and Wissen Research Analysis.
1. Introduction
1.1 Key Objectives
1.2 Definitions
1.2.1 In Scope
1.2.2 Out of Scope
1.3 Scope of the Report
1.4 Scope Related Limitations
1.5 Key Stakeholders
2. Research Methodology
2.1 Research Approach
2.2 Research Methodology / Design
2.3 Market Sizing Approach
2.3.1 Secondary Research
2.3.2 Primary Research
3. Executive Summary & Premium Content
3.1 Global Market Outlook
3.2 Key Market Findings
4. Market Overview
4.1 Market Dynamics
4.1.1 Drivers/Opportunities
4.1.2 Restraints/Challenges
4.2 End User Perception
4.3 Need Gap
4.4 Supply Chain / Value Chain Analysis
4.5 Industry Trends
4.6 Porter’s Five Forces Analysis
5. Global Pharmaceutical CDMO Market by, Product Type (2023-2030, USD Million)
5.1 Pharmaceutical Manufacturing Services Market
5.1.1 Active Pharmaceutical Ingredient (API) Manufacturing Services Market
5.1.1.1 By Type
5.1.1.1.1 Traditional API
5.1.1.1.2 High Potency API
5.1.1.1.3 Antibody Drug Conjugate
5.1.1.1.4 Others
5.1.1.2 By Synthesis
5.1.1.2.1 Natural
5.1.1.2.2 Synthetic
5.1.1.3 By Drug Type
5.1.1.3.1 Generic
5.1.1.3.2 Innovative
5.1.1.4 By Manufacturing
5.1.1.4.1 Batch Manufacturing
5.1.1.4.2 Continuous Manufacturing
5.2.1 Finished Dosage Formulation (FDFs) Manufacturing Services Market
5.2.1.1 By Dosage Form
5.2.1.1.1 Solid
5.2.1.1.1 Capsules
5.2.1.1.2 Tablets
5.2.1.1.3 Powder
5.2.1.2 Semi-Solid
5.2.1.2.1 Paste
5.2.1.2.2 Cream
5.2.1.2.3 Gel
5.2.1.3 Liquid
5.2.1.3.1 Injectable / Parenteral
5.2.1.3.2 Suspensions
5.2.1.3.3 Emulsion
5.2.1.3.4 Others (Nasal Spray and Solutions)
5.1.2 By Drug Type
5.1.2.1 Generic
5.1.2.2 Innovative
5.1.3 By Manufacturing Type
5.1.3.1 Batch Manufacturing
5.1.3.2 Continuous Manufacturing
5.3 Pharmaceutical Drug Development Services Market
5.3.1 API Development Services Market
5.3. 2 FDF Development Services Market
6. Global Pharmaceutical CDMO Market by, Dosage Form (2023-2030, USD Million)
6.1 Solid
6.1.1 Capsules
6.1.2 Tablets
6.1.3 Powder
6.2 Semi-solid
6.2.1 Paste
6.2.2. Cream
6.2.3 Gel
6.3 Liquid
6.3.1 Injectable / Parenteral
6.3.2 Suspensions
6.3.3 Emulsion
6.3.4 Others (Nasal Spray and solutions)
6.4 Others (Gas formulations)
7. Global Pharmaceutical CDMO Market by, Operations (2023-2030, USD Million)
7.1 Clinical
7.2 Commercial
8. Global Pharmaceutical CDMO Market by, Therapeutic Modality (2023-2030, USD Million)
8.1 Small Molecules
8.2 Biologics
9. Global Pharmaceutical CDMO Market by, End-user (2023-2030, USD Million)
9.1 Small Pharmaceuticals
9.2 Mid-sized Pharmaceuticals
9.3 Large Pharmaceuticals
10. Global Pharmaceutical CDMO Market by, Region (2023-2030, USD Million)
10.1 North America
10.1.1 US
10..1.2 Canada
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Spain
10.2.4 Italy
10.2.5 UK
10.2.6 Rest of the Europe
10.3 Asia-Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia and New Zealand
10.3.5 South Korea
10.3.6 Rest of the Asia-Pacific
10.4 Middle East and Africa
10.5 Latin America
11. Competitive Analysis
11.1 Key Players Footprint Analysis
11.2 Market Share Analysis
11.3 Key Brand Analysis
11.4 Regional Snapshot of Key Players
11.5 R&D Expenditure of Key Players
12. Company Profiles2
12.1 Thermo Fisher Scientific, Inc.
12.1.1 Business Overview
12.1.2 Product Portfolio
12.1.3 Financial Snapshot3
12.1.4 Recent Developments
12.1.5 SWOT Analysis
12.2 Recipharm AB
12.3 Lonza
12.4 Catalent, Inc.
12.5 Samsung Biologics
12.6 Bushu Pharmaceuticals Ltd.
12.7 Curia
12.8 Pfizer Centre One
12.9 Laboratory Corporation of America Holdings (LabCorp)
12.10 Siegfried Holding AG
12.11 CordenPharma International
12.12 WuXi AppTec, Inc.
12.13 Piramal Pharma Solutions
12.14 Sequens
12.15 Cambrex Corporation
13. Conclusion
14. Appendix
14.1 Industry Speak
14.2 Questionnaire
14.3 Available Custom Work
14.4 Adjacent Studies
14.5 Authors
15. References
Key Notes:
